Corneal Intrastromal Implantation Surgery by means of MyoRing Corneal Implant for the Treatment of Keratoconus: A Review

ABSTRACT
This review provides information about MyoRing treatment of keratoconus (KC). MyoRing is a complete ring implant that is inserted into the cornea via a narrow lamellar entrance between two corneal layers at 300 μm depth beneath the corneal surface. Since MyoRing is a complete ring it can achieve both visual rehabilitation and stop of progression. The procedure is very safe and effective and lasts only 10 to 15 minutes. It is performed under topical anesthesia and is intra- as well as postoperatively free of pain. Complications are extremely rare.

Keywords: Cornea, Intracorneal ring, Keratoconus, MyoRing.

How to cite this article: Macsek M, Steinberg J, Linke S, Arnalich F, Alberti M, Daxer A. Corneal Intrastromal Implantation Surgery by means of MyoRing Corneal Implant for the Treatment of Keratoconus: A Review. Int J Kerat Ect Cor Dis 2018;7(1):50-60.

Source of support: Nil

Conflict of interest: None

KERATOCONUS

Keratoconus is a progressive, noninflammatory disease of the cornea characterized by vision loss, irregular corneal shape, and corneal thinning.1

Symptoms, Diagnosis, and Epidemiology

Symptoms
In the early clinical stages, irregular deformations of the corneal surface lead to slightly blurred vision and sometimes increased sensitivity to bright lights. When progressing, vision may become more and more distorted due to increasing myopia and higher order aberrations including irregular astigmatism. Because of the inter-eye asymmetry in KC, usually one eye demonstrates noticeably worse symptoms.

Frequently occurring symptoms in clinical manifest KC (i.e., KC stages including morphological changes of the corneal surface/topography) are:

- Distorted vision at all distances
- Noticeably worse vision in one eye
- Double vision in one eye
- “Ghost” images—the appearance of several images when looking at one object
- Shadows—typically like a comet tail (also known as “vertical coma”)
- Poor night vision
- Increased light sensitivity

Diagnosis
Defined as a progressive, bilateral ectasia of the cornea, the diagnosis of KC is originally based on changing refraction and morphological signs diagnosed with the slit lamp (iron deposition in the epithelial basement membrane “Fleischer rings”), breaks in Bowman’s layer (Vogt’s striae) and focal corneal thinning.1

The development of specialized diagnostic devices focusing on the corneal curvature (especially the Placido-Topography in 1880) helped to identify this ectatic disease in earlier stages (i.e., before gross morphological changes at the slit lamp occur).2 Retrospectively, especially two independent developments gave rise to a growing interest and further improvement of KC diagnostics. The increased numbers of corneal-refractive procedures after the introduction of excimer laser vision correction in the late 1980s and corneal cross-linking (CXL), as the first sufficient therapy to stop the progression of KC, in the late 1990s.3 Although screening for advanced KC with corneal topography is a straightforward procedure, screening eyes with subclinical KC (scKC) (i.e., early stages without clinically relevant topographic characteristics) remains challenging.4 However, because even subtle topographical changes potentially lead to a decline of...
the visual acuity, further strategies have been adopted to identify KC especially on a subttopographical level. Unfortunately, because of the absence of an objective, device-independent and up-to-date classification, the definition of “normal,” scKC, and early KC is not coherent in current studies, leading to a distinct bias of the reported results.5

A standard method in current scKC screening is the corneal tomography: Using scanning slit-based devices—(Orbscan®), Scheimpflug, or optical coherence tomography (OCT)—techniques, different devices enable a high-resolution examination and analysis of the entire corneal morphology.6 Concentrating on current, high-published studies, especially point-by-point corneal thickness (progression) analyses and the analysis of posterior elevation pattern reaches an area under the receiver operating characteristic curve (AUROC) of up to 0.91 for scKC screening.7 Another study, concentrating on epithelial changes in scKC by using OCT could demonstrate an AUROC of up to 0.985.8

A different diagnostic approach is wavefront analyses: With this technique, point-by-point corneal curvature analyses of the anterior and posterior corneal surface are utilized to calculate mathematical wavefront patterns, subdivided and analyzed as Zernike polynomials. Thereby, Saad and Gatinel9 and Bühren et al10 demonstrated an AUROC of 0.985 (Saad) and 0.956 (Bühren) to distinguish between normal and scKC eyes with topographically only minor irregularities. Saad and Gatinel9 and Bühren et al10 used different definitions of scKC. Whereas Saad and Gatinel9 defined both groups using the automated corneal classification software of a corneal topographic analyzing system (OPD-Scan, NIDEK Co. Ltd., Gamagori, Japan), Bühren et al10 defined their scKC by an inferior-superior value of <1.4 and other topographic patterns, and their NE by retrospectively analyzed Orbscan analyses of patients with an uneventful post-LASIK follow-up of 12 months or more.

The latest approach to improve scKC screening is in vivo biomechanical analyses. The aim of this methodology is to identify KC even before changes of the corneal morphology occur. With the ocular response analyzer (ORA®, Reichert) and the corneal visualization Scheimpflug technology (CST®, Oculus), two different devices have been developed trying to detect an irregular kinetic response of the cornea to an applied air-puff-impulse (CST: Scheimpflug technology, high-speed camera/single air-impulse; ORA: Infrared signal peaks/pulsed jet of air turned off after the application of the cornea).11

Whereas the original ORA analyzed mainly two parameters (corneal hysteresis and corneal resistance factor), the current version (2.0) analyzes the deformation dynamics of the cornea, such as height, slope, and width, using 37 “wavefront” parameters. A current study by Luz et al12 reports an AUROC of up to 0.721 ± 0.065 to identify (topographically normal) KC eyes with the ORA-wavefront parameters.

The latest CST version offers a Corvis biomechanical index’ (CBI) as the most comprehensive index. Currently, there are no studies available analyzing scKC vs normal eyes.13 However, studies are in progress testing the capability of the CBI alone and in combination with Pentacam indices generating a combined topographical and biomechanical index to improve scKC screening. Recent combinations of the ORA and tomographical analyses demonstrated an AUROC of up to 0.95.7

In conclusion, the corneal topography and tomography represent the gold standard in KC screening and other techniques should be used as second line/complementary device. However, especially the combination of biomechanical analyses with advanced topography/tomography devices seem to have the ability to further improve early (i.e., subclinical/subtopographical) KC screening.

Epidemiology

Stated by Woodward et al,14 “the most frequently cited occurrence of KC is 1:2,000. This value is based on a registration study in the United States that was conducted from 1935 until 1982. This study reported a prevalence of 54.5 cases per 100,000 individuals.”15

Reviewing epidemiological data on KC, two things should be kept in mind: The time when the data were collected (because the improvement of the diagnostic devices) and the region the data originated/ethnic heterogeneity of the population (because of different cultural influences regarding the intrafamily sexual reproduction).

An example for the diversity of current data are two register studies from European countries: A nationwide registration study to the age-specific incidence and prevalence of KC conducted in the Netherlands based on data from an insurance company covering 30% (>4.3 million) of the residents reported an annual incidence of KC of 1:7,500 in persons between 10 and 40 years of age with an estimated prevalence in the general population of 1:375. The mean age at the diagnosis was 28 years and the male/female-ratio was 6/4.16

A Danish registry study from 2007 analyzing the entire population based on their entry in the National Patient Registry revealed an incidence of 1.3/100,000 and a prevalence of 87/100,000.17

The published world-wide prevalence ranges from 1/500,000 (Urals, Russia)18 to 2.3% (Central India,
combined with a high prevalence of consanguinity)\textsuperscript{19} and 3.2% (Israel).\textsuperscript{20}

A study analyzing sociodemographic factors in KC patients including over 16,000 records from a nationwide United States managed care network using multivariable regression modeling to account for confounding factors could demonstrate a higher odds ratio of KC in Black (57%) and Latinos (43%) compared with Whites, whereas Asian Americans presented a 39% lower odds than Whites.\textsuperscript{31} In contrast to the American study including Asian Americans, two studies analyzing the UK population revealed a higher odds ratio for Asians than Whites [4.4 and 7.5 higher odds for (mostly Muslim) Indian, Pakistani, and Bangladeshi].\textsuperscript{21,22}

Common findings in epidemiological studies include a higher risk of male vs female (about 6:4), of patients with sleep apnea, atopic disease/asthma, or Down syndrome (up to 6:1). For diabetes mellitus, a decreasing risk of 20 to 50%, depending on the severity of the disease, could be identified.\textsuperscript{14,23}

Next to all these epidemiological data it is important to understand that, because of the young onset of this chronic disease (mean age at diagnosis equals approximately 28 years\textsuperscript{16,24}), even modest visual deficits often lead to a disproportionate impact on quality of life and the economic burden of the treatment of KC represents a significant public health concern.\textsuperscript{25,26}

Ultrastructure and Biomechanics of the Cornea

The cornea consists roughly of five principal components: Epithelium, Bowman’s membrane, stroma, Descemet membrane (DM), and endothelium. The stroma represents some 90% of the corneal thickness and is commonly understood as the “corneal tissue”. This unique connective tissue is avascular, transparent, and has an immune privilege.\textsuperscript{27} It is responsible for the transparency and the regular shape of the cornea and therefore, for the optical properties of the eye, as well as for the refractive state of the eye (in connection with the axial length) and for the biomechanics of the cornea. The corneal stroma is stacked in some 200 consecutive lamellae of type I collagen fibrils.\textsuperscript{28} Within each lamella, the collagen fibrils run parallel to each other and shows short-range ordered arrangement, which is responsible for the corneal transparency.\textsuperscript{29} The orientation and arrangement of the successively stacked collagen lamellae throughout the entire stroma maintains the biomechanics of the tissue and constitutes the shape of the cornea and the optical function of the eye.\textsuperscript{30} When approaching the periphery of the cornea, the collagen fibrils turn into a circular path forming the limbus.\textsuperscript{31} These ultrastructural properties result in a much higher stiffness at the limbus compared with the cornea and in the spherical dome model of the cornea, which considers the cornea to be mounted at the limbus.\textsuperscript{32} This knowledge is helpful in calculating the effect of corneal implants on the biomechanics of the cornea.\textsuperscript{33}

TREATMENT METHODS

Contact Lens

The first description of using contact lenses (CLs) to correct the optics in KC is found from the physician and physiologist Fick.\textsuperscript{34} Nowadays CL fitting is an essential part of providing the appropriate optical rehabilitation in different stages of KC and can be a great improvement of patients’ quality of life.\textsuperscript{35} However, it remains a complex and challenging process. Whereas patients in the early stages of KC might be sufficiently treated with spectacles, CLs are the mainstay of nonsurgical visual correction in advanced KC.\textsuperscript{36} Although the variety of available CL has greatly expanded,\textsuperscript{37} rigid gas-permeable (RGP) CLs still are the mainstay and most common treatment option especially in early to moderate stages of KC.\textsuperscript{38} The mode of action for RGP CL is masking corneal irregularities, reducing higher order aberrations and thereby improving visual acuity. The selection of the proper CL has to be based on various parameters including material and design. The goal is to achieve a smooth interaction with the keratoconic cornea.\textsuperscript{39}

Previous studies have already brought up the concern that a prolonged use of CL alters the underlying corneal cell morphology in healthy as well as in keratoconic corneas.\textsuperscript{40} Mechanical injury to the corneal epithelium caused by CL on a keratoconic cornea is believed to result in the release of proapoptotic cytokines comparable to the process demonstrated after CXL\textsuperscript{41} or photorefractive keratectomy.\textsuperscript{42} Pre-CL fitting assessment of the individual corneal shape and evaluation of the transparency of the cornea are essential. The analysis of the corneal shape has greatly improved over the last decades. Placido- and Scheimpflug imaging have become the gold standard techniques to diagnose KC, monitor progression, and optimize CL fitting.\textsuperscript{5} Recently new emerging technologies beyond Scheimpflug-corneal tomography, such as anterior segment OCT provide additional \textit{in vivo} microstructural information for the clinician and CL fitter.\textsuperscript{36}

The CL modalities for KC include soft and rigid design and material: The major limitation of traditional soft CL is the reduced ability to mask irregular astigmatism. Given these circumstances, the use of traditional soft CL is limited to scKC and early stages of KC.\textsuperscript{43} Recently,
custom-made, aberration-controlled soft CL designs have been developed. Rigid CLs maintain the architectural structure on the eye. Therefore, they create a thin lacrimal lens between the irregular anterior corneal surface and the posterior lens surface. This results in reducing the astigmatic error but does not necessarily normalize higher-order aberrations.

As published by Downie and Lindsay in their comprehensive review on CL management of KC, after a period of focusing on rigid corneal lenses, the previous 20 to 30 years are characterized by CL practice paying more and more attention to rigid lens modalities with larger diameter, such as corneo-scleral and miniscleral lenses. These devices bear the advantage of enhanced on-eye stability and decreased lens awareness. Consistent effort has been paid to optimize the design of rigid CL used for the treatment of KC. On the one hand, a steeper back optic zone radius (BOZR) is supposed to fit the conical nature of the central cornea and to reduce the touch at the corneal apex. On the contrary, peripheral curves with progressively flatter radii are supposed to clear the peripheral cornea. The most common design of rigid CL has been the multicurve lens, which consists of multiple spherical radii.

This design bears the advantage of readily changeable parameters including the BOZR, total lens diameter, back peripheral curve radii, back peripheral curve widths, and back optic zone diameter. In addition, due to improvements in manufacturing and technology, aspheric lenses are also available for the optical correction in patients with KC. In KC a significant asymmetry in the corneal contour is usually found; therefore, quadrant-specific lens designs, with different edge lifts incorporated into each quadrant of the lens are another innovation in rigid lens designs. As mentioned before, CL fitting remains a demanding task. Comorbidities, such as atopic diseases, including eczema, asthma, and allergic rhinoconjunctivitis, can present major hurdles to successful CL wear and should therefore, be controlled by timely and appropriate ophthalmic care. Innovation in imaging technologies, such as corneal topography, OCT, and in vivo confocal microscopy, has improved CL fitting. In conclusion, contemporary advances in diagnostics, CL designs, and materials are continuously expanding the range of therapeutic options in patients with corneal irregularity.

Cross-linking

Introduced in 1998, CXL represented the first therapy for KC, offering a biomechanical strengthening of the otherwise ectatic and thereby destabilizing cornea. Despite the absence of a global consensus on when to use CXL in KC, the most consistent criterion in the literature is an increase of the maximum keratometry (Kmax) of ≥1 D. Further (inhomogeneous) criteria include an increase of the spherical equivalent or astigmatism and decrease of visual acuity. The principle of CXL is to create oxygen free radicals, which initiate the cross-linking by bridging (mainly) amino groups between corneal collagen fibers. To start this biochemical process, a photosensitizer (riboflavin, vitamin B2) is applied within the corneal stroma and is then activated by the irradiation with an ultraviolet-A (UV-A; 370 nm) source. Therefore, from a biochemical perspective, the CXL represents an intrastromal photopolymerization process.

The first CXL procedure was named “Dresden protocol” because of its introduction at the Technical University of Dresden (Dresden, Germany) by Wollensak et al. This protocol, which is still considered as the standard CXL protocol, includes the removal of the central 9 mm of corneal epithelium and an application of 0.1% riboflavin for 30 minutes. After ensuring a minimal corneal thickness of 400 μm and a completely riboflavin-impregnated corneal stroma, the procedure continues by applying riboflavin for another 30 minutes combined with an energy fluence of 5.4 J/cm² (3 mW/cm²) of UV-A light delivered in the corneal tissue.

Since the introduction of the Dresden protocol, numerous long-term studies have been demonstrated its high safety and efficacy. After establishing the original protocol, current studies concentrate on further improving the methodology. These approaches mainly include performing the CXL without removing the epithelium (“epi-on”-CXL), accelerating the treatment (A-CXL), and/or to customize it by focusing the CXL on the cone area (C-CXL).

The main reason for focusing on potential transepithelial or “epi-on-CXL” - protocols is the hope to decrease the post-CXL pain-level, infection-rate, and wound healing-related problems after the epithelial removal without compromising the effectiveness of the epi-off-CXL. The main obstacle in epi-on-CXL is the high blocking property of the epithelium for UV-A and for large hydrophilic molecules like riboflavin. Studies on epi-off-CXL could demonstrate that the desired stiffening effect is achieved by a sufficient treatment penetration of 250 to 300 μm of stromal depth. Despite achieving the desired perioperative benefits of the epi-on-strategy, up to date, even with enhanced riboflavin solutions or iontophoresis-assisted protocols, no epi-on-CXL procedure reaches this amount of cross-linked volume, potentially indicating a decreased (long-term) efficacy. However, new protocols including different UV-A applications (pulsed/different wave lights) and the supplementary use of oxygen and/
or ozone to increase the intrastromal radical-creation are currently under review. The accelerated strategies (A-CXL) focus on the potential benefit of shortening the treatment time of 60 minutes of the original protocol by increasing the irradiation intensity. Although current research could demonstrate the safety and short-term efficacy of A-CXL, a current review article analyzing different irradiation settings refers to several studies, which consistently demonstrate the appearance of more superficial demarcation lines when shortening the exposure time (and simultaneously increasing the energy-dose), suggesting a reduced (volume-based) stiffening of the cornea.

The C-CXL represents a different approach: Using an eye-tracker-guided adjustable UV-A source and preoperative topography/tomography data, customized energy profiles can be projected onto the cornea. These protocols are based on the assumption that there is no need to strengthen the entire cornea, but only the biomechanical weakened area to avoid a progressive destabilization in KC eyes. Thereby, the weaker parts have to be treated with a higher intensity to ensure the necessary strengthening of the tissue. Analyzing C-CXL compared with the standard Dresden protocol, two different study groups report a significantly stronger decrease of Kmax and a significantly higher regularization of the corneal surface with equally deep demarcation lines in the cone-area one year after the treatment. Encouraged by their results, Seiler et al discussed the possibilities of further customization of the treatment to potentially improve the individual refractive outcome. However, up to date, only 1-year follow-up data are available comparing C-CXL and the Dresden-protocol-CXL. Long-term analyses have to prove the equality of both protocols especially in terms of long-term biomechanical stabilization. To sum up, despite all the upcoming, highly interesting modifications, presently, the original Dresden-“epi-off”-CXL remains the gold standard in increasing the biomechanical properties in progressive KC eyes, especially when the young patient presents with a good uncorrected- or spectacle/CL-corrected visual acuity.

Intracorneal Ring Segments

Intracorneal ring segments (ICRSs) are small implants of polymethylmethacrylate plastic available in numerous arc-lengths, thickness, and designs. They were initially designed to correct low myopia in normal eyes but since first used by Colin et al for KC, their most common indication is the treatment of ectatic corneal disease. They function as spacers elements between the collagen fibers of the cornea and therefore, induce an arc shortening effect of the corneal geometry that induces a flattening at the central area of the cornea and a regularization of the asymmetry of the tissue. These changes lead to a reduction in the keratometric readings and an improvement in the refraction and vision of KC patients.

Indications for ICRS implantation are a corrected distance visual acuity below 0.9 in the decimal scale, inability to use CLs, and the absence of a visually significant central leucoma.

Two main types of ICRSs are being used nowadays for the treatment of ectatic corneal disease, different in profile and diameter of implantation: INTACS (Addition technologies) with a hexagonal cross section, 6.77 inner diameter, and a single arc length of 150°, and Kerarings (Mediphacos) with a triangular cross section, 5 or 6 mm inner diameter, and different arc lengths from 90° up to 340°. Thickness of the intracorneal rings ranges from 0.25 to 0.35 mm with INTACS and 0.15 to 0.35 with Kerarings.

There are several implantation nomograms, but the most used are the ones developed by the main manufacturers of ICRS in order to decide the number, arc length, thickness, and position of the segments in the cornea. Frequently, authors advocate implanting the corneal ring guided by the steepest meridian, but others prefer to guide implantation by the comatic axis. The ICRSs are inserted into stromal tunnels at a desired depth of between 60 and 80% either manually using a handheld corkscrew blade or automatically using a femtosecond laser.

Most of the studies on ICRS implantation for the treatment of KC have reported an improvement in the uncorrected and corrected visual acuity, a reduction in the spherical equivalent and cylinder, a flattening of keratometric readings between 3 and 5 D, and a positive impact in optical quality by reducing anterior corneal higher order aberrations, such as coma and coma like. In a multicentric study it was shown that the worse the visual impairment at the time of the surgery the better the results, while patients with fairly good visual acuity were more prone to lose lines of visions after the procedure. Regression and further progression is found 5 years after ICRS treatment and is often a cause for ICRS explantation.

Implanting ICRS in keratoconic patients is a safe surgical procedure specially when using femtosecond laser to create the tunnels. During surgery, segment decentration, asymmetric positioning of the ICRS, or inadequate depth of the tunnels are the main complications. After the surgery there has been described segment migration and extrusion, corneal neovascularization, corneal melting, infectious keratitis,
and hydrops. Often it is found a white deposit around the segment inside the tunnels composed of fatty acids and that produces no visual impairment.

**Corneal IntraStromal Implantation System/MyoRing**

Corneal IntraStromal Implantation System (CISIS) including MyoRing is a newer technology characterized by creating a lamellar pocket and insertion of a complete full-ring implant (MyoRing) into this pocket via a lamellar incision. Both the surgical technique and the implant itself is different from ICRS. This technology was developed to overcome the shortcomings of ICRS in order to avoid ICRS-related complications, such as extrusions, to improve visual rehabilitation and to achieve long-term stability and to stop progression; CISIS/MyoRing is described in detail in Chapter 3.

**Keratoplasty**

The traditional choice of treatment for advanced KC is a corneal graft. However, there is no general consensus for the definition of advanced disease. Most corneal specialists would agree that corneal transplant would be advisable when the optical correction with spectacles is insufficient, when continued CL wear is intolerable, or when corrected visual acuity has reduced to unacceptable levels. The percentage of KC patients requiring a corneal transplantation is estimated to be 12 to 20%.

Traditionally penetrating keratoplasty (PK) has been the primary choice. Recently, deep anterior lamellar keratoplasty (DALK) techniques are becoming more popular as it reduces intrasurgical risks from open-sky surgery, and almost disappears the risk of immunological rejection or late progressive endothelial cell loss. The reported visual and refractive outcomes in PK and DALK seem to be equivalent, although a vision of 20/20 might be more likely after PK. Taking the disadvantages of DALK like a given surgical inexperience, certain issues concerning the residual stromal thickness and DM folds into consideration, the advantages mentioned before compensate for this difference. One major issue when performing DALK remains the intraoperative perforation of the DM, which may occur in up to 50% of the eyes. Risk factors therefore, are corneal scarring near the DM, corneal ectasias with a remaining corneal thickness of less than 250 μm as well as an inexperienced surgeon. The presence of a double anterior chamber secondary to breaks in DM, interface haze, interface infectious keratitis, and interface vascularization has also been described in DALK surgery.

In conclusion, elective PK should be reserved for those cases when the DM and the endothelium appear splitted (e.g., after a corneal hydrops) or when there is scarring involving the DM. It may also be a better option in cases of surgeon inexperience or clinics with a low volume of keratoplasty surgery.

**CORNEAL INTRASTROMAL IMPLANTATION SYSTEM/MYORING**

**Surgical Procedure**

As described elsewhere, an intrastromal pocket is created by means of the PocketMaker Ultrakeraatome at a depth of 300 μm with a diameter of 9.0 mm. A lamellar incision of 5.0 mm width is created whereas the pocket stays closed along the remaining circumference in order to preserve the biomechanics of the tissue. The criterion for safe use of the PocketMaker Ultrakeraatome in order to avoid corneal perforation is a corneal thickness of at least 350 μm at the thinnest point. Via the lamellar incision the MyoRing is implanted into the intrastromal pocket. The MyoRing is produced of modified polymethylmethacrylate.

The selection of the right MyoRing dimension (diameter and thickness) is performed by processing the eye exam data securely uploaded online to DIOPTEX. The calculation is based on a sophisticated corneal model proven and optimized by more than 5,000 treatments. In order to achieve the best possible result in any given case the surgeons should follow the related treatment guidelines.

The PocketMaker Ultrakeraatome is in particular designed for the optimal performance of the CISIS/MyoRing surgical procedure. The procedure can alternatively also be performed via a femtosecond laser instead of the PocketMaker Ultrakeraatome. However, since the quality of the cutting-interface created by means of the femtosecond laser at 300 μm depth is much lower than that of the PocketMaker Ultrakeraatome the visual results and the therapeutic index are limited. The PocketMaker uses a vibrating diamond blade guided on micron level with an extremely precise cutting edge so that the cut interface in the tissue is perfectly smooth. In contrast the corneal pocket created by the femtosecond laser is essentially not smoothly cut but disrupted. This results in a comparably rough interface and less effectiveness in utilizing the appropriate MyoRing dimension for establishing an improved corneal shape when using the femtosecond laser.

**Visual Rehabilitation**

Inserting the MyoRing into the corneal pocket forces the cornea central to the MyoRing into a more regular shape.
and because of the perfect interface between the anterior and the posterior lamellae created by the PocketMaker Ultrakeratome; both lamellae glide against each other into a new and stable biomechanical equilibrium.\(^8\) The new corneal shape after treatment is relatively stable 3 months after initial surgery.\(^8\) Depending on the preoperative visual acuity the improvement of uncorrected visual acuity can range from 1 to 20 lines. In order to be able to achieve the best possible result in any given case it is important to calculate the individually right implant dimension via the company’s online tools and to follow the optimized treatment guidelines. The procedure eliminates the negative impact of the positioning of the implant on the results as seen in ICRS treatment since it allows positioning according to the real postoperative optical axis.\(^8\) The long-term results of CISIS/MyoRing treatment of KC show that there is virtually no regression (progression) but even further improvement of the visual result over time.\(^78,84\) The explanation is that due to the natural rigidity of the tissue the corneal shape centrally to the MyoRing is much more regular after surgery but may not be perfectly regular immediately after the surgery. However, intraocular pressure permanently pushes the corneal tissue against the MyoRing, which results in a continuous “ironing” of the remaining corneal irregularities into a more regular shape day by day and year by year within the closed boundaries of the MyoRing.\(^78,84\) According to the mathematical discipline called topology the excellent visual rehabilitation in KC treatment by means of CISIS is therefore, the result of both, the regular and uniform cross section along the circumference of the MyoRing and the fact that the MyoRing is a complete and continuous ring.\(^77,83\) This effect is shown in Graphs 1 and 2 by shifting the linear regression line of the visual improvement toward the ideal line of visual correction of 20/20 vision over time. It is also important to note that CISIS/MyoRing is equal effective in both, central and non-central KC.\(^85\)

**Biomechanics of CISIS/MyoRing**

As explained in chapter “Ultrastructure and Biomechanics of the cornea” the collagen fibrils of the cornea turn into a circular direction when approaching the corneal periphery and the limbus. This results in an increased modulus of elasticity (Young’s modulus) and stabilizes the cornea there. The cornea can therefore, be considered as mounted on the limbus.\(^32\) When inserting the MyoRing into the cornea at 300 μm depth the intraocular pressure pushes the convex front-surface of the MyoRing into the anterior stromal lamellae and compresses the stroma right in front of the MyoRing from 300 to 70 μm. That process anchors the implanted MyoRing in the stroma. The MyoRing is a continuous and complete ring, which defines a plane of mechanical support in the direction of the laminar forces inside the cornea. The MyoRing therefore, acts as a second limbus inside the cornea and therefore, stabilizes the cornea accordingly.\(^33\) In contrast to cross-linking that stabilizes the cornea by changing the elastic properties of the cornea at an ultrastructural level, the MyoRing acts as an additional support, which is able to take up the forces acting inside the cornea. It can be considered in analogy of a cast around a broken leg or a ceiling beam, which supports the ceiling in a house. This is only possible because the MyoRing is a complete

---

**Graph 1:** Linear regression analysis of line improvement vs preoperative uncorrected distance visual acuity 1 year (red) and 5 years (blue) after treatment. The dotted line represents the potential for maximum improvement to 1.0 (20/20) visual acuity. The shift of the regression line toward the dotted line demonstrates further significant improvement of visual acuity. Data taken from Daxer et al.\(^75\)

**Graph 2:** Linear regression analysis of line improvement vs preoperative corrected distance visual acuity 1 year (red) and 5 years (blue) after treatment. The dotted line represents the potential for maximum improvement to 1.0 (20/20) visual acuity. The shift of the regression line toward the dotted line demonstrates further significant improvement of visual acuity. The data were from Daxer et al.\(^78\)
Corneal Intrastromal Implantation Surgery by means of MyoRing Corneal Implant

and continuous ring implant. It is of course not possible if a ring implant is incomplete, such as ICRS. This quality is important to explain the long-term stability (Graphs 2 and 3) of CISIS/MyoRing treatment of KC.78,84

Essentially it is possible to combine CISIS/MyoRing and cross-linking to achieve both visual rehabilitation and stop of progression.86,87 However, the MyoRing alone can strengthen the cornea by a factor of three without performing cross-linking (Graph 4). The combination of CISIS/MyoRing and cross-linking should therefore, be reserved to the very unlikely event only of progression after CISIS/MyoRing treatment.78,87

Complications and Side-effects

Side-effects after treatment include postoperative glare and halos, over- or undercorrection, and decentration of the MyoRing.

Over- or undercorrection as well as decentration of the MyoRing will usually result in an exchange of the implanted MyoRing. According to the published literature,78,82,84,88 this occurs in between 10 and 24% of cases.

Glare and halos are reported by the patients especially in the early postoperative phase. Prangl-Grötzl et al84 report that about 37% of patients complain of disturbing glare after 3 to 5 months postoperatively. However, the number of patients reporting halos is reduced to merely 20% after 1 year, while this side-effect was not evaluated as being disturbing significantly.

Possible complications after the implantation of a MyoRing are very rare in the hand of a trained surgeon and include perforation of the cornea, extrusion of the MyoRing, or infections. There is no published data on severe complication. One group reported the performing of keratoplasty (2 out of 48 eyes) or the removal of the MyoRing (1 out of 48 eyes) after the initial implantation of a MyoRing due to patient dissatisfaction.88 It is therefore, important to inform patients who suffer from very advanced KC, which is beyond the treatment range of MyoRing (average central K > 60) that the postoperative visual acuity after treatment may be not satisfactory and that keratoplasty may be the right choice in such a case. Complication rates according to the experience of the authors of this review estimate the incidence of extrusion (<1%), corneal infection (<0.1%), or corneal perforation (<0.1%) to be very low.

CONCLUSION

As conclusion of this information we propose an optimized treatment scheme and a related grading for KC.

Grade I: Uncorrected visual acuity ≥ 0.8 (20/25) and no progression
Action: No treatment

Grade II: Uncorrected visual acuity ≥ 0.8 (20/25) and progression
Action: CXL*

Grade III: Uncorrected visual acuity < 0.8 (20/25) but corrected visual acuity ≥ 0.8 (20/25) and no progression
Action: CISIS/MyoRing** or glasses or CL

Grade IV: Uncorrected visual acuity < 0.8 (20/25) but corrected visual acuity ≥ 0.8 (20/25) and progression and corneal thickness ≥ 400 μm
Action: CISIS/MyoRing or [(glasses or CL) plus cross-linking]

Grade V: Uncorrected visual acuity < 0.8 (20/25) but corrected visual acuity ≥ 0.8 (20/25) and progression and corneal thickness < 400 μm
Action: CISIS/MyoRing**
Grade VI: Corrected visual acuity < 0.8 (20/25) and no progression
   Action: CISIS/MyoRing** or CL
Grade VII: Corrected visual acuity < 0.8 and progression and corneal thickness ≥ 400 μm
   Action: CISIS/MyoRing** or (cross-linking plus CL)
Grade VIII: Corrected visual acuity < 0.8 and progression and corneal thickness < 400 μm
   Action: CISIS/MyoRing**
Grade IX: Corneal thickness < 350 μm and CL tolerated
   Action: Keratoplasty
   *if corneal thickness ≥ 400 μm: a criterion that is expected to be always fulfilled at that stage of the disease.
   **if corneal thickness is ≥350 μm.

REFERENCES

Corneal Intrastromal Implantation Surgery by means of MyoRing Corneal Implant


